Superoxide Dismutase Glycation: A Contributor to Disease and Target for Prevention
Catalysts · 05.03.2025 · 15 (3) · 247
DOI: 10.3390/catal15030247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catalysts, online erschienen am 05.03.2025. Verfasst von Masood Alam Khan und 1 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Superoxide dismutase (SOD), a key antioxidant enzyme, plays a crucial role in neutralizing reactive oxygen species (ROS) and maintaining redox balance. However, SOD is highly susceptible to glycation, a non-enzymatic modification induced by reducing sugars and reactive carbonyl species such as methylglyoxal. This review aims to provide a comprehensive analysis of SOD glycation, examining its biochemical mechanisms, its impact on enzymatic function, and its role in the progression of oxidative stress-related diseases. Additionally, it explores potential therapeutic strategies to prevent SOD glycation and restore its activity, highlighting translational applications for disease management. The review examines research on SOD glycation and its pathological consequences in diabetes complications, neurodegenerative disorders, and cardiovascular diseases. Key therapeutic interventions, including advanced glycation end-product (AGE) inhibitors (aminoguanidine, pyridoxamine), antioxidants (N-acetylcysteine, alpha-lipoic acid), SOD mimetics (MnTBAP, Tempol), enzyme stabilizers (thymoquinone, alliin), and receptor for advanced glycation end-products (RAGE) blockade, are analyzed for their efficacy in mitigating oxidative stress. SOD glycation reduces enzymatic activity, leading to elevated ROS levels and inflammation. Glycated SOD interacts with RAGE, increasing oxidative stress biomarkers. AGE inhibitors reduce carbonyl stress, whereas antioxidants lower ROS levels. SOD mimetics restore up to 85% of enzymatic activity, and enzyme stabilizers protect SOD from structural degradation. Additionally, monoclonal antibodies targeting RAGE have been shown to reduce inflammatory cytokines and improve mitochondrial function. SOD glycation is a major contributor to oxidative stress-related diseases. Preventing glycation and restoring SOD function through a multifaceted therapeutic approach is crucial for mitigating disease progression. By elucidating the role of SOD in disease pathogenesis, this review contributes to the advancement of targeted therapies for oxidative stress-related conditions, including diabetes, neurodegeneration, and cardiovascular diseases.
Zitieren
APA
Khan, M. A., & Younus, H. (2025). Superoxide Dismutase Glycation: A Contributor to Disease and Target for Prevention. Catalysts, 15(3), 247. https://doi.org/10.3390/catal15030247
Vancouver
Khan MA, Younus H. Superoxide Dismutase Glycation: A Contributor to Disease and Target for Prevention. Catalysts. 2025;15(3):247. doi:10.3390/catal15030247
BibTeX
@article{Khan2025,
author = {Khan, Masood Alam and Younus, Hina},
title = {Superoxide Dismutase Glycation: A Contributor to Disease and Target for Prevention},
journal = {Catalysts},
year = {2025},
volume = {15},
number = {3},
pages = {247},
doi = {10.3390/catal15030247}
}
EUVIMED